Second hit mutations in the RTK/RAS signaling pathway in acute myeloid leukemia with inv(16)

Haematologica

Volumn 89, Issue 1, 2004, Pages 106-

  Valk, Peter J M ^a   Bowen, David T ^b   Frew, Marion E ^b   Goodeve, Anne C ^c   Löwenberg, Bob ^a   Reilly, John T ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NINEWELLS HOSPITAL   (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

AML; C KIT; FLT3; Inv(16); RAS

Indexed keywords

FLT3 LIGAND; PROTEIN TYROSINE KINASE; RAS PROTEIN; RETINOIC ACID RECEPTOR ALPHA; STEM CELL FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ANIMAL MODEL; ARTICLE; CHROMOSOME 16Q; CHROMOSOME INVERSION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; NONHUMAN; ONCOGENE N RAS; PATHOGENESIS; SIGNAL TRANSDUCTION;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; CHROMOSOMES, HUMAN, PAIR 16; FEMALE; HUMANS; INVERSION, CHROMOSOME; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 0842328518     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Castilla LH, Garrett L, Adya N, Orlic D, Dutra A, Anderson S, et al. The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukemia. Nat Genet 1998;23:144-6.
2. Kogan SC, Lagasse E, Arwater S, Bae SC, Weissman I, Ito Y, et al. The PEBP2β MYH11 fusion created by inv(16)(p13;q22) in myeloid leukemia impairs neutrophil maturation and contributes to granulocytic dysplasia. Proc Natl Acad Sci USA 1998;95:11863-8.
3. Gilliland DG. Hematologic malignancies. Curr Opin Hematol 2001;8:189-91.
4. Care RS, Valk PJM, Goodeve AC, Abu-Duhier FM, Geertsma-Kleinekoort WM, Wilson GA, et al. Incidence and prognosis of c-kit and flt3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol 2003;121;775-7.
5. Gari M, Goodeve A, Wilson G, Winship P, Langabeer S, Linch D, et al. C-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol 1999;105:894-900.
6. Kottaridis PD, Gale RE, Langabeer SE, Frew ME, Bowen DT, Linch DC. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukaemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection and possible therapy with FLT3 inhibitors. Blood 2002;100:2393-8.
7. Kelly LM, Kutok JL, Williams IR, Boulton CL, Amaral SM, Curley DP, et al. PML/RARα and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci USA 2002;99:8283-8.
8. Neubauer A, Dodge RK, George SL, Davey FR, Silver RT, Schiffer CA, et al. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood 1994;83:1603-11.
9. Radich JP, Kopecky KJ, Willman CL, Weick J, Head D, Appelbaum F, et al. N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance. Blood 1990;76:801-7.
10. Reuter CW, Morgan MA, Bergmann L. Targeting the Ras signalling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 2002;96:1655-69.